BioSpace News Archive

Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announces positive topline data from its phase 2 study evaluating safety, tolerability, and efficacy of imlifidase in reducing donor specific antibodies (DSAs) in patients with active and chronic active antibody mediated rejection (AMR) episodes.

Vulvovaginal Candidiasis (VVC) is one of the most common infections among women, affecting around 138 million women annually worldwide.

The global acute care telemedicine market was surpassed at USD 17.62 billion in 2021 and is expected to hit around USD 60.34 billion by 2030, growing at a CAGR of 14.66% from 2022 to 2030.

The global microbiome sequencing outsourcing services market is expected to register significant growth over the forecast period. Microbiomes are microorganisms living in the human body.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of positive patient-reported outcome itch data from its Phase 2b study evaluating once-daily roflumilast cream (0.3% and 0.15%) in adults with chronic plaque psoriasis.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, has been nominated as the company’s first development candidate in the RAS pathway.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI).

Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the rationale and design of the Company’s ongoing SHIMMER clinical trial of CT1812 will be presented at the 2022 Clinical Trials in Alzheimer’s Disease (CTAD) conference.

ContraFect Corporation (Nasdaq: CFRX) announces today that ANSM, the French National Agency for the Safety of Medicines and Health Products, has authorized its Clinical Trial Application (CTA) for the study of intra-articularly administered exebacase.

TC BioPharm today announced that it has entered into a securities purchase agreement with healthcare-focused and institutional investors for the sale and issuance in a private placement of 1,470,000 American Depositary Shares.